$0.69
Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
Overview
52-week range
$0.85
$2.93
0% of range
Avg surprise (last 3)
-7.3%
Avg reaction (last 2)
+0.9%
50% positive
Latest IV / EM
1635%
EM ±374.1% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 4, 2026 | Mar/2026 | $-0.16 | $-0.19 | +15.8% | +27.3% | +1.7% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.17 | — | — | — | — | financials |
| Mon Aug 4, 2025 | Jun/2025 | $-0.26 | $-0.24 | -8.3% | — | — | earnings |
| Fri May 9, 2025 | Mar/2025 | $-0.22 | $-0.17 | -29.4% | — | 0.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.16 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.22 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.21 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.15 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.24 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 3, 2026 | Jun/2026 | OTHER | -$0.20 | -$0.26 | +23.1% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | $687,000 | — | $864,000 | $313,000 | $292,000 | — | $414,000 | $331,000 |
| Operating income | $-14M | — | $-13M | $-13M | $-11M | — | $-8M | $-8M |
| Net income | $-14M | — | $-13M | $-13M | $-11M | — | $-8M | $-8M |
| EPS (diluted) | $-0.16 | — | $-0.17 | $-0.26 | $0.22 | — | $-0.16 | $-0.22 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11M | $9M | $63M | $12M | $12M | $19M | $16M | $28M |
| Inventory | $3M | $3M | $4M | $3M | $3M | $3M | $2M | $2M |
| Total current assets | $49M | $61M | $70M | $25M | $32M | $41M | $46M | $52M |
| Total assets | $56M | $69M | $78M | $33M | $39M | $47M | $50M | $56M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $13M | $14M | $14M | $13M | $10M | $11M | $9M | $9M |
| Total equity | $44M | $55M | $64M | $20M | $28M | $36M | $41M | $47M |